The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
A multicentre validation study of the diagnostic value of plasma neurofilament light.
Open accessPublished version of a preprint
Abstract
Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King’s College London ( n = 805) and the Swedish BioFINDER study ( n = 1,464). Plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical parkinsonian disorders. We demonstrate that plasma NfL is clinically useful in identifying atypical parkinsonian disorders in patients with parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment. Data-driven cut-offs highlighted the fundamental importance of age-related clinical cut-offs for disorders with a younger age of onset. Finally, plasma NfL performs best when applied to indicate no underlying neurodegeneration, with low false positives, in all age-related cut-offs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Phosphorylated tau (p-tau) is the leading blood biomarker candidate, demonstrating superior diagnostic accuracy and disease specificity compared with other candidates.3,4”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, blood measures of p-tau181, p-tau217, p-tau231, glial fibrillary acid protein (GFAP), neurofilament light (NfL) and Aβ42/40 have been shown to change in preclinical AD and can discriminate this state from CU individuals with non-AD pathological changes1,3,6–13.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As expected, plasma NfL had relatively lower PPV and NPV for AD, as NfL is a nonspecific biomarker of neurodegeneration, elevated in multiple different neurodegenerative diseases44.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationBrown, R. H., & Al-Chalabi, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1603471 · Cited by 2,125
Self-citationNeurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationAssociation of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Self-citationBiomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Self-citationDominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
Research works printed but not linked: 1
- Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. J. Am. Med. Assoc. 324, 772–781, https://doi.org/10.1001/jama.2020.12134 (2020). · DOI · Paper page
Cited by
Biomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citationDiagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5319 · Cited by 884
Self-citationPlasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Self-citationHansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citation
Metadata
- Authors
- Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., Galimberti, D., Bonanni, L., Pilotto, A., Padovani, A., Lycke, J., Novakova, L., Axelsson, M., Velayudhan, L., Rabinovici, G. D., Miller, B., Pariante, C., Nikkheslat, N., Resnick, S. M., Thambisetty, M., Schöll, M., Fernández-Eulate, G., Gil-Bea, F. J., López de Munain, A., Al-Chalabi, A., Rosa-Neto, P., Strydom, A., Svenningsson, P., Stomrud, E., Santillo, A., Aarsland, D., van Swieten, J. C., Palmqvist, S., Zetterberg, H., Blennow, K., Hye, A., & Hansson, O.
- Affiliations
- King's College London (GB)
- Lund University (SE)
- University of Gothenburg (SE)
- Montreal Neurological Institute and Hospital (CA)
- Instituto de Salud Carlos III (ES)
- University of Perugia (IT)
- University of Milan (IT)
- University of Chieti-Pescara (IT)
- Fondazione Europea Ricerca Biomedica (IT)
- University of Brescia (IT)
- Sahlgrenska University Hospital (SE)
- University of Leicester (GB)
- University of California, San Francisco (US)
- National Institutes of Health (US)
- UCL Queen Square Institute of Neurology (GB)
- Corresponding author
- Ashton, Nicholas J.
- Hansson, Oskar
- ORCID
- Ashton, Nicholas J.
- Janelidze, Shorena
- Al Khleifat, Ahmad
- Leuzy, Antoine
- Karikari, Thomas K.
- Pascoal, Tharick A.
- Lleó, Alberto
- Parnetti, Lucilla
- Galimberti, Daniela
- Bonanni, Laura
- Pilotto, Andrea
- Padovani, Alessandro
- Lycke, Jan
- Novakova, Lenka
- Axelsson, Markus
- Velayudhan, Latha
- Rabinovici, Gil D.
- Miller, Bruce
- Pariante, Carmine
- Nikkheslat, Naghmeh
- Resnick, Susan M.
- Thambisetty, Madhav
- Schöll, Michael
- Fernández-Eulate, Gorka
- Gil-Bea, Francisco J.
- Al-Chalabi, Ammar
- Svenningsson, Per
- Stomrud, Erik
- Santillo, Alexander
- Aarsland, Dag
- Palmqvist, Sebastian
- Zetterberg, Henrik
- Blennow, Kaj
- Hye, Abdul
- Hansson, Oskar
- Venue
- Nature Communications
- Published
- 2021-06-07
- Volume
- 12
- Issue
- 1
- Pages
- 3400-3400
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8185001
- OpenAlex
- W3167068736
- Cited by
- 545
- References
- 69
- Citations by year
- 2026: 74 · 2025: 116 · 2024: 125 · 2023: 102 · 2022: 92 · 2021: 35
- FWCI
- 65.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Parkinson Research Foundation
- Eli Lilly and Company
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- Torsten Söderbergs Stiftelse
- South London and Maudsley NHS Foundation Trust (MR/L501529/1, ES/L008238/1, 633413)
- Wellcome Trust (MR/S005145/1, FP7/2007–2013, MR/R024901/1, 098330, 098330/Z/12/Z)
- Health Research Board (JPI-JPND-2017-1)
- EU Joint Programme – Neurodegenerative Disease Research (MR/L501529/1)
- Cytokinetics
- Australian Government
- Apellis Pharmaceuticals
- National Institute for Health and Care Research (ES/L008238/1, FP7/2007–2013, MR/L501529/1, NIHR202421)
- Motor Neurone Disease Association (ALCHALABI-TALBOT/APR14/926-794, 633413, 259867, 772376, ALCHALABI-DOBSON/APR14/829-791, MR/L501529/1, Al-Chalabi/Apr19/870-791, FP7/2007-2013, ES/L008238/1)
- King's College London
- European Commission (2007–2013, FP7 2007-2013, HORIZON2020, H2020, FP7/2007, H2020-PHC-2014, 633413, H2020-PHC, 772376, 259867)
- Agence Nationale de la Recherche (ANR-18-COEN-0002, ANR-17-JPCD-0001)
- Stiftelsen för Strategisk Forskning
- Lunds Universitet
- Kommunfullmäktige, Stockholms Stad
- Hjärnfonden
- Knut och Alice Wallenbergs Stiftelse (681712)
- Vetenskapsrådet (FP7/2007-2013, 681712, 02532, 2018-, ALFGBG-720931, 2018-02532)
- Göteborgs Universitet
- Alzheimerfonden
- Skånes universitetssjukhus
- Marcus och Amalia Wallenbergs minnesfond
- Mitsubishi Tanabe Pharma Corporation
- UK Dementia Research Institute
- Demensfonden
- National Institutes of Health (FP7/2007-2013, 2018-02532, H2020)
- Parkinsonfonden
- Horizon 2020 Framework Programme (FP7/2007-2013, 633413, 772376, H2020-PHC-2014)
- Sanofi Genzyme
- Avid Radiopharmaceuticals
- NIHR Maudsley Biomedical Research Centre (ES/L008238/1, MR/L501529/1, 633413)
- Medical Research Council (FP7/20072013, 259867, ES/L008238/1, MRC S011277/1, MR/S011277/1, MR/S005145/1, MR/R024901/1, MR/R024804/1, MR/L501529/1)
- Economic and Social Research Council (ES/L008238/1, L008238, MR/L501529/1, 633413, FP7/2007-2013)
- National Institute on Aging (P30AG066507)
- H2020 European Research Council (681712)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- plasma neurofilament light, neurodegeneration biomarkers, neurodegenerative diseases, atypical parkinsonism, Down syndrome, dementia, depression, frontotemporal dementia, amyotrophic lateral sclerosis, diagnostic accuracy, neurofilaments
- MeSH terms
- Age Factors, Aged, Depression, Down Syndrome, False Positive Reactions, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Reference Values, Sex Factors, Cohort Studies, Biomarkers, Neurofilament Proteins, Neurodegenerative Diseases, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multicentre validation study of the diagnostic value of plasma neurofilament light. https://app.cochat.ai/papers/10.1038/s41467-021-23620-z
- The paper
- Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., Galimberti, D., Bonanni, L., Pilotto, A., Padovani, A., Lycke, J., Novakova, L., Axelsson, M., Velayudhan, L., Rabinovici, G. D., . . . Hansson, O. (2021). A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications. https://doi.org/10.1038/s41467-021-23620-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.